As veterinarians we understand the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is essential.

Osteoarthritis (OA) describes inflammation of a joint and can occur after single or repetitive episodes of trauma, or be pre-disposed to it by OCD lesions. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis (OA). Sub-chondral bone injury also plays a role. These pathological conditions are ‘a group of overlapping distinct diseases which may have different aetiologies, but with similar biologic, morphologic, and clinical outcomes.’

Although conventional concepts of OA emphasise the direct and predominant involvement of cartilage and bone in OA development, it is increasingly recognised that the synovium also contributes to the central pathophysiological event of cartilage matrix depletion.

Cases suitable for treatment with Arthramid® Vet are those in which lameness is localised to the joint by clinical examination and intra-articular analgesia, together with radiography, ultrasound, MRI, CT and/or Scintigraphy. Conditions that we have seen respond to treatment with Arthramid® Vet include acute and chronic synovitis, capsulitis, meniscal tears, OA, and even subchondral bone cysts (personal communications).

It is essential that anamnesis of data of ongoing infection, concomitant medication, surgery or potential fracture is reviewed prior to injection to prevent possible infections or use of a product for conditions other than for which they are indicated.

To find out more about case selection or how to start using Arthramid Vet 2.5% iPAAG in your practice, contact us. We have a panel of expert veterinarians available from around the world to help you and your patients get the best from this innovative new product.

Dr Jason Lowe BVSc, Cert EP